1
|
Qiu Q, Yu X, Chen Q, He X. Sema3A inactivates the ERK/JNK signalling pathways to alleviate inflammation and oxidative stress in lipopolysaccharide-stimulated rat endothelial cells and lung tissues. Autoimmunity 2023; 56:2200908. [PMID: 37128697 DOI: 10.1080/08916934.2023.2200908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Semaphorin 3A (Sema3A) is a secretory member of the semaphorin family of immune response regulators. This research focuses on its effects on inflammation and oxidative stress in acute respiratory distress syndrome (ARDS). By analysing the GEO dataset GSE57011, we obtained Sema3A as the most downregulated gene in ARDS samples. Lipopolysaccharide (LPS) was used to stimulate rat pulmonary microvascular endothelial cells (PMVECs) and rats to induce ARDS-like symptoms in vitro and in vivo, respectively. LPS induced severe damage in rat lung tissues, in which reduced immunohistochemical staining of Sema3A was detected. Sema3A overexpression reduced apoptosis and angiogenesis of LPS-induced PMVECs and alleviated lung injury and pulmonary edoema of rats. Moreover, ELISA results showed that Sema3A overexpression downregulated the levels of inflammatory cytokines and oxidative stress markers both in PMVECs and the rat lung. Activation of ERK/JNK signalling aggravated LPS-induced damage on PMVECs; however, the aggravation was partly blocked by Sema3A, which suppressed phosphorylation of ERK/JNK. Overall, this study demonstrates that Sema3A inactivates the ERK/JNK signalling to ameliorate inflammation and oxidative stress in LPS-induced ARDS models. Sema3A might therefore represent a candidate option for ARDS treatment.
Collapse
Affiliation(s)
- Qianwen Qiu
- Department of Medical Ultrasonics, Lishui People's Hospital, Lishui, Zhejiang, P.R. China
| | - Xiufeng Yu
- Department of Emergency Medicine, Lishui People's Hospital, Lishui, Zhejiang, P.R. China
| | - Qingli Chen
- Department of Emergency Medicine, Lishui People's Hospital, Lishui, Zhejiang, P.R. China
| | - Xuwei He
- Department of Emergency Medicine, Lishui People's Hospital, Lishui, Zhejiang, P.R. China
| |
Collapse
|
2
|
Role for ERK1/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis. Proc Natl Acad Sci U S A 2018; 115:E9570-E9579. [PMID: 30249660 DOI: 10.1073/pnas.1810209115] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Clathrin-mediated endocytosis (CME) regulates the uptake of cell-surface receptors as well as their downstream signaling activities. We recently reported that signaling can reciprocally regulate CME in cancer cells and that this crosstalk can contribute to cancer progression. To further explore the nature and extent of the crosstalk between signaling and CME in cancer cell biology, we analyzed a panel of oncogenic signaling kinase inhibitors for their effects on CME across a panel of normal and cancerous cells. Inhibition of several kinases selectively affected CME in cancer cells, including inhibition of ERK1/2, which selectively inhibited CME by decreasing the rate of clathrin-coated pit (CCP) initiation. We identified an ERK1/2 substrate, the FCH/F-BAR and SH3 domain-containing protein FCHSD2, as being essential for the ERK1/2-dependent effects on CME and CCP initiation. Our data suggest that ERK1/2 phosphorylation activates FCHSD2 and regulates EGF receptor (EGFR) endocytic trafficking as well as downstream signaling activities. Loss of FCHSD2 activity in nonsmall cell lung cancer (NSCLC) cells leads to increased cell-surface expression and altered signaling downstream of EGFR, resulting in enhanced cell proliferation and migration. The expression level of FCHSD2 is positively correlated with higher NSCLC patient survival rates, suggesting that FCHSD2 can negatively affect cancer progression. These findings provide insight into the mechanisms and consequences of the reciprocal regulation of signaling and CME in cancer cells.
Collapse
|
3
|
Xu Y, Xia J, Liu S, Stein S, Ramon C, Xi H, Wang L, Xiong X, Zhang L, He D, Yang W, Zhao X, Cheng X, Yang X, Wang H. Endocytosis and membrane receptor internalization: implication of F-BAR protein Carom. Front Biosci (Landmark Ed) 2017; 22:1439-1457. [PMID: 28199211 DOI: 10.2741/4552] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Endocytosis is a cellular process mostly responsible for membrane receptor internalization. Cell membrane receptors bind to their ligands and form a complex which can be internalized. We previously proposed that F-BAR protein initiates membrane curvature and mediates endocytosis via its binding partners. However, F-BAR protein partners involved in membrane receptor endocytosis and the regulatory mechanism remain unknown. In this study, we established database mining strategies to explore mechanisms underlying receptor-related endocytosis. We identified 34 endocytic membrane receptors and 10 regulating proteins in clathrin-dependent endocytosis (CDE), a major process of membrane receptor internalization. We found that F-BAR protein FCHSD2 (Carom) may facilitate endocytosis via 9 endocytic partners. Carom is highly expressed, along with highly expressed endocytic membrane receptors and partners, in endothelial cells and macrophages. We established 3 models of Carom-receptor complexes and their intracellular trafficking based on protein interaction and subcellular localization. We conclude that Carom may mediate receptor endocytosis and transport endocytic receptors to the cytoplasm for receptor signaling and lysosome/proteasome degradation, or to the nucleus for RNA processing, gene transcription and DNA repair.
Collapse
Affiliation(s)
- Yanjie Xu
- Center Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nan Chang, Jiang Xi, 330006, China, and Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Jixiang Xia
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Suxuan Liu
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140,and Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China
| | - Sam Stein
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Cueto Ramon
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Hang Xi
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Luqiao Wang
- Center Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nan Chang, Jiang Xi, 330006, China, and Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Xinyu Xiong
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Lixiao Zhang
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Dingwen He
- Department of Orthopedics, Second Affiliated Hospital of Nanchang University, Nan Chang, Jiang Xi, 330006, China
| | - William Yang
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140
| | - Xianxian Zhao
- Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China
| | - Xiaoshu Cheng
- Center Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nan Chang, Jiang Xi, 330006, China
| | - Xiaofeng Yang
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140, and Cardiovascular Research, Temple University School of Medicine, Philadelphia, PA, 19140, and Thrombosis Research, Temple University School of Medicine
| | - Hong Wang
- Center for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA, 19140, and Cardiovascular Research, Temple University School of Medicine, Philadelphia, PA, 19140, and Thrombosis Research, Temple University School of Medicine,
| |
Collapse
|